Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Midazolam intranasal - Proximagen

Drug Profile

Midazolam intranasal - Proximagen

Alternative Names: ITI-111; Midazolam Nasal Spray - Proximagen; NAYZILAM; USL-261

Latest Information Update: 23 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intranasal Therapeutics
  • Developer Ikano Therapeutics; Proximagen
  • Class Antiepileptic drugs; Benzodiazepines; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seizures
  • New Molecular Entity No

Highest Development Phases

  • Registered Seizures
  • Phase I Epilepsy
  • Discontinued Anaesthesia; Anxiety disorders; Mild cognitive impairment

Most Recent Events

  • 20 May 2019 Adverse events and efficacy data from the phase III ARTEMIS1 trial in Seizures released by UCB
  • 20 May 2019 Registered for Seizures (In adolescents, In adults) in USA (Intranasal)
  • 01 Apr 2019 UCB receives complete response letter from the FDA for midazolam intranasal spray for Seizures
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top